Curis Lifesciences Ltd (CURIS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: CURIS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

Curis Lifesciences Ltd (CURIS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 0 | NSE: CURIS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Curis Lifesciences

Based on:

M-Cap below 100cr DeciZen not available

Curis Lifesciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
15.25
Market Cap:
93.1 Cr.
52-wk low:
0
52-wk high:
0

Is Curis Lifesciences Ltd an attractive stock to invest in?

1. Is Curis Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Curis Lifesciences Ltd is a average quality company.

2. Is Curis Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Curis Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Curis Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Curis Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Curis Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Curis Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 17.1%21%40.2%34.3%-
Value Creation
Index
0.20.51.91.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 23.835.535.649.149
Sales YoY Gr.-49.3%0.3%38.2%-
Adj EPS 0.93.48.910.37.6
YoY Gr.-282%162.1%15.5%-
BVPS (₹) -1.61.810.727.322.7
Adj Net
Profit
0.51.94.96.16
Cash Flow from Ops. 53.40.3-1.8-
Debt/CF from Ops. 3.64.861-8.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA27.4%38.2%
Adj EPS NANA126.1%15.5%
BVPSNANANA156%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-54.13654.4142.555.330.2
Op. Profit
Mgn %
15.29.323.919.4NAN
Net Profit
Mgn %
2.15.313.812.412.4
Debt to
Equity
-19.516.12.91-
Working Cap
Days
01672011970
Cash Conv.
Cycle
020501080

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 27.42%

Net Profit is growing at healthy rate in last 3 years 126.12%

Debt to equity has declined versus last 3 years average to 0.96

Return on Equity has declined versus last 3 years average to 30.20%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Curis Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 7.6 -
TTM Sales (₹ Cr.) 49.1 -
BVPS (₹.) 22.7 -
Reserves (₹ Cr.) 10 -
P/BV 5.07 -
PE 15.25 -
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 93.1
Equity (₹ Cr.) 8.1
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Curis Lifesciences:

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Valuation of Curis Lifesciences - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Curis Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales23.7535.4535.5649.13
Operating Expenses 20.1432.1427.1139.58
Manufacturing Costs6.4712.3311.2816.12
Material Costs9.4316.2211.9619.34
Employee Cost 3.222.182.743.11
Other Costs 1.031.401.131.03
Operating Profit 3.603.318.449.55
Operating Profit Margin (%) 15.2%9.3%23.7%19.4%
Other Income 0.020.970.310.51
Interest 1.641.360.901.12
Depreciation 0.750.730.680.67
Exceptional Items 0000
Profit Before Tax 1.232.197.178.27
Tax 0.730.312.312.16
Profit After Tax 0.491.884.876.11
PAT Margin (%) 2.1%5.3%13.7%12.4%
Adjusted EPS (₹)0.93.48.910.3
Dividend Payout Ratio (%)0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund -0.901.015.8716.23
Share Capital 0.500.500.505.93
Reserves -1.400.515.3710.29
Minority Interest0000
Debt1614.8615.8314.65
Long Term Debt12.419.788.707.50
Short Term Debt3.605.097.137.16
Trade Payables9.2811.076.905.95
Others Liabilities 3.022.805.275.70
Total Liabilities 27.4029.7533.8842.53

Fixed Assets

Gross Block15.3515.9115.9816.06
Accumulated Depreciation3.013.714.395.07
Net Fixed Assets 12.3312.2011.5910.99
CWIP 0000.02
Investments 0.010.010.010.01
Inventories5.385.118.9618.40
Trade Receivables6.249.5510.107.52
Cash Equivalents 0.110.150.420.30
Others Assets 3.332.742.805.29
Total Assets 27.4029.7533.8842.53

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 4.953.350.28-1.76
PBT 1.232.197.178.27
Adjustment 2.372.031.521.77
Changes in Working Capital 1.35-0.87-8.41-10.24
Tax Paid 000-1.56
Cash Flow From Investing Activity -0.37-0.56-0.06-0.02
Capex -0.38-0.58-0.07-0.09
Net Investments 0000
Others 0.010.020.010.07
Cash Flow From Financing Activity -4.58-2.760.051.67
Net Proceeds from Shares 0004.25
Net Proceeds from Borrowing -3.14-2.63-1.07-1.20
Interest Paid -1.62-1.33-0.85-1.11
Dividend Paid 0000
Others 0.181.201.97-0.27
Net Cash Flow -0.010.040.27-0.11

Finance Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)N/A3669.86141.5155.25
ROCE (%)N/A20.9640.2234.25
Asset Turnover Ratio0.871.241.121.29
PAT to CFO Conversion(x)10.11.780.06-0.29
Working Capital Days
Receivable Days968110165
Inventory Days835472102
Payable Days359229274121

Curis Lifesciences Ltd Stock News

Curis Lifesciences Ltd FAQs

The current trading price of Curis Lifesciences on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Curis Lifesciences stood at ₹93.13.
The latest P/E ratio of Curis Lifesciences as of 31-Dec-1969 is 15.25.
The latest P/B ratio of Curis Lifesciences as of 31-Dec-1969 is 5.07.
The 52-week high of Curis Lifesciences is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Curis Lifesciences is ₹49.13 ( Cr.) .

About Curis Lifesciences Ltd

Curis Lifesciences was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 (Partnership Act) in the name and style of ‘M/s Loreto Pharmaceuticals’, pursuant to a deed of partnership dated June 2, 2010. Thereafter ‘M/s Loreto Pharmaceuticals’ was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of ‘Curis Lifesciences Private Limited’ on March 23, 2016. Subsequently, the company was converted into a public limited company and the name of the company was changed from ‘Curis Lifesciences Private Limited’ to ‘Curis Lifesciences Limited’ vide Special Resolution dated May 6, 2024, the status of the company was changed to public limited and the fresh certificate of incorporation consequent to conversion was issued on August 9, 2024.

It is a pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, etc. It operates in global as well as domestic markets. It undertakes manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. 

The company's business is bifurcated in three catagories such as, in Loan License Manufacturing, all raw materials and excipients are procured and delivered by the client. Further, the client provides the company with necessary supporting documents and formulations. On instructions of the client, the company undertakes manufacturing activities under observation of a chemist, representing the customer.

In Contract Manufacturing, the company would be responsible for procuring and handling all ingredients, raw materials, and packaging materials. Further, all necessary supporting documents and formulations required under manufacturing process would be procured / provided by it. However, the client, is responsible for providing the brand name and product composition. Moreover, all marketing and distribution responsibilities rests with the client. 

In Direct Export/Own Brand Manufacturing, it manufactures products registered by itself in foreign country and sells the said products in foreign country through its distribution network. All ingredients, including raw materials and packaging materials, are purchased and handled by our company. Additionally, we are responsible for all marketing and distribution activities. The brand name and product composition is owned by the company only.

Business area of the company

The company is engaged in the pharma manufacturing. It specializes in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, Oral Liquid, etc. It undertakes manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. It operates in global as well as domestic markets.

Products of the company

  • Tablet
  • Capsule
  • External Preparation (Cream/Gel/Ointment)
  • Oral Liquid 
  • Sterile Ophthalmic Ointment

History and millstones

  • 2010-11: Started Business by starting a Partnership Firm with two Partners in name of ‘M/s Loreto Pharmaceutical’ by Dasharathbhai Patel and Piyush Gordhanbhai Antala.
  • 2015-16: The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23, 2016.
  • 2017-18: The Company received FDA License for manufacturing Pharma products. 
  • 2018-19: The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 
  • 2019-20: The Company received WHO GMP certificate. 
  • 2020-21: The Company received FDA Approval from Philippines during the tragic era of COVID-19 
  • 2021-22: Renewal of the WHO Certificates and Nigeria NAFDAC Approval 
  • 2022-23: Retention of FDA License for manufacturing Pharma products. 
  • 2024-25: Conversion From Private Limited into Public Limited company.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×